November 4, 2008
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director, President and Chief Executive Officer

Cephalon Receives FDA Approval for TREANDA® to Treat Patients with Relapsed Indolent
Non-Hodgkin's Lymphoma
TREANDA® Receives Second Indication this Year;
Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have
Progressed Following a Rituximab-Containing Regimen
FRAZER, Pa., Oct. 31 -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Foodand Drug Administration (FDA) has approved TREANDA® (bendamustine hydrochloride)for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma(NHL) that has progressed during or within six months of treatment with rituximab or arituximab-containing regimen. The data supporting the FDA approval show that TREANDA®
is effective, has a tolerable side effect profile in patients with indolent NHL and thattreatment results in a high durable response rate. In March of this year, TREANDA® received
approval for the treatment of patients with chronic lymphocytic leukemia, the most common
form of leukemia in the United States.
Indolent NHL, a subset of non-Hodgkin's lymphoma, is a slow growing but serious cancer ofthe lymphatic system that is not curable with currently available treatments. Patients withindolent NHL are prone to multiple relapses after initial therapy. According to the National
Cancer Institute, an estimated 30,000 people in the United States will be diagnosed this yearwith indolent NHL.
"Because most patients with indolent non-Hodgkin's lymphoma eventually become resistant
to existing treatments, new treatment options like TREANDA® are needed to improve patient
outcome," stated Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital,Washington, D.C. and TREANDA® clinical investigator. "The TREANDA® pivotal trial showsthat it is an effective and well-tolerated chemotherapy that offers a delay in diseaseprogression for more than nine months."

According to Dr. Lesley Russell, Executive Vice President and Chief Medical Officer, Cephalon,"We are excited about this second FDA approval for TREANDA® in 2008. This approval ofTREANDA® for indolent non-Hodgkin's lymphoma is a significant milestone in ourdevelopment of a diverse oncology portfolio of products that improve patient outcomes."
The FDA approval is supported by a pivotal trial of 100 patients with indolent B-cell NHL
who had progressed during or within six months of treatment with a regimen that included
rituximab. The pivotal study demonstrated that patients had a high response rate totreatment with TREANDA®, and these responses to the treatment were durable. The resultsfrom the pivotal study showed that treatment with TREANDA® as a single agent resulted inan overall response rate of 74 percent, which means that after treatment, the cancer
diminished or disappeared in approximately three out of four patients. Additionally, patient
response to treatment in the pivotal study lasted a median of 9.2 months and patientsremained alive and their disease did not progress for a median of 9.3 months.
The safety of TREANDA® is also supported by a secondary monotherapy study. In the pivotal
and secondary studies for TREANDA® in indolent NHL, the most common non-hematologic
adverse reactions (frequency > 15%) are nausea, fatigue, vomiting, diarrhea, pyrexia,constipation, anorexia, cough, headache, weight decrease, dyspnea, rash and stomatitis. The
most common hematologic abnormalities (frequency >15%) are lymphopenia, leukopenia,anemia, thrombocytopenia and neutropenia.
In addition to its proven efficacy and tolerable side effect profile, TREANDA® has aconvenient dosing schedule as a treatment for indolent NHL. An intravenous infusion takes
60 minutes and can be administered in an outpatient setting, reducing the time it takes forpatients to be treated. The recommended dose for indolent NHL is 120 mg/㎡ administered ondays one and two of a 21-day cycle, for up to eight cycles.

[About Bendamustine hydrochloride]
Cephalon holds exclusive rights to market and develop TREANDA® in the United States.
TREANDA® is licensed from Astellas Deutschland GmbH. SymBio Pharmaceuticals Ltd holds
exclusive rights to develop and market bendamustine HCl, the active ingredient inTREANDA® in Japan, China, Korea, Taiwan and Singapore and is now conducting a Phase II
clinical trial of SyB L-0501 at 18 facilities, with patients who have relapsed/refractoryindolent non-Hodgkin’s lymphoma. Bendamustine HCl is marketed in Germany by Astellas'
licensee, Mundipharma International Corporation Limited. In Germany, bendamustine isindicated as a single-agent or in combination with other anti-cancer agents for indolent NHL,
multiple myeloma, and CLL.

[Company Profile]
SymBio Pharmaceuticals Ltd. was established in March 2005 by Fuminori Yoshida, whopreviously served as both Corporate VP of Amgen Ltd. and President of Amgen Japan(currently Takeda Bio Development Center Limited). The company’s underlying
corporate philosophy is “delivering hope to patients in need,” and the company aims toaddress the unmet medical needs of patients in Japan and other Asia Pacific regions bycultivating a mutually beneficial or symbiotic relationship among physicians, scientists,investors, government, and patients in the healthcare industry.
[Contact]
SymBio Pharmaceuticals Limited.
Osamu Ogawa,
Board Director, Senior Corporate Officer,Senior Director, Research & Development
Tel: +081(0)3 5472 1127
e-mail: Please send your inquiry through “INQUIRY” in our homepage
URL: http://www.symbiosis.co.jp